Roche Launches FDA-Cleared PCR Test for Women's Health
Roche (RHHBY) has received U.S. Food and Drug Administration (FDA) clearance under the 510(k) pathway for its cobas BV/CV assay, a polymerase chain reaction (PCR)-based test designed to detect bacterial vaginosis and Candida vaginitis using a single vaginal swab sample. The new diagnostic tool aims to improve accuracy and speed in diagnosing common gynecological infections. Roche's expansion into women’s health reflects its broader strategy to strengthen its presence in the diagnostics market, particularly with innovative solutions that address unmet clinical needs. This development is expected to enhance patient care by enabling faster diagnosis and treatment decisions for healthcare providers.
Tickers: $ROP